1 / 6

The Viral Vaccines Market

According to a recent report by Meticulous Researchu00ae, the viral vaccines market is expected to reach $47.01 billion by 2031, growing at a CAGR of 1.9% from 2024 to 2031. This growth is driven by a robust pipeline of vaccine products, increased government emphasis on immunization programs, technological advancements in vaccine delivery, and the expanded use of inactivated vaccines in surgeries and treatments. Additionally, capacity expansions in biopharmaceuticals, a rising focus on therapeutic vaccines, the growing use of adjuvants, opportunities in emerging markets, and the development of sta

Prajwal26
Télécharger la présentation

The Viral Vaccines Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “Meticulous Research® Projects Viral Vaccines Market $47.01 Billion by 2031” pen_spark” J

  2. Viral Vaccines Market 2024-2031 Viral Vaccines Market Set to Reach $47.01 Billion by 2031: Key Growth Drivers, Trends, and Competitive Insights Meticulous Research®, a globally recognized leader in market intelligence, has released a comprehensive new report titled "Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized), Type (Live Attenuated, mRNA, Inactivated), Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging – Global Forecast to 2031." According to the findings, the global viral vaccines market is projected to reach an impressive $47.01 billion by 2031, with a CAGR of 1.9% from 2024 to 2031. Download FREE PDF Brochure Of Viral Vaccines Market :- https://www.meticulousresearch.com/download-sample- report/cp_id=5920?utm_source=article&utm_medium=social&utm_campaign= product&utm_content=02-10-2024 This report offers in-depth insights into market dynamics, drivers, challenges, and opportunities for key stakeholders. It highlights the factors shaping the market, such as the ongoing development of a strong vaccine pipeline, increasing governmental focus on immunization initiatives, technological advancements in vaccine administration, and the growing use of inactivated vaccines in surgical and treatment settings. Additionally, the report identifies emerging trends that are expected to propel market growth. These include the rising focus on therapeutic vaccines, the expanded use of vaccine adjuvants, significant growth opportunities in emerging markets, and the development of ultra-low temperature freezers that are highly stable and energy-efficient. Market Segmentation: A Deep Dive 1. Market by Form: Liquid Vaccines Lead Based on the form, the viral vaccines market is segmented into liquid vaccines and lyophilized vaccines. In 2024, the liquid vaccines segment is anticipated to command the largest market share. This dominance can be attributed to several key advantages, including ease of administration, reduced risk of errors, and simplified logistics compared to lyophilized vaccines. Liquid vaccines eliminate the need for reconstitution, lowering contamination risks and minimizing the Page 1 of 5 © Meticulous Research| sales@meticulousresearch.com

  3. Viral Vaccines Market 2024-2031 requirement for specialized training and equipment. With the growing prevalence of infectious diseases, liquid vaccines offer a convenient and cost- effective solution that reduces vaccine wastage and optimizes healthcare outcomes. 2. Market by Vaccine Type: Subunit & Conjugate Vaccines Drive Growth The viral vaccines market is also categorized by vaccine type, including live- attenuated vaccines, inactivated vaccines, mRNA vaccines, viral vector vaccines, subunit & conjugate vaccines, toxoid vaccines, and combination vaccines. Among these, the subunit & conjugate vaccines segment is poised to secure the largest share of the market by 2024. The absence of live microorganisms, precise targeting of pathogens, and low risk of immunogenicity make subunit vaccines highly attractive. Their ability to elicit protective immune responses and provide long-term immunity further strengthens their market position. 3. Market by Virus Type: Adenovirus Leads the Charge Within the virus type segment, adenovirus vaccines are expected to dominate the market by 2024, capturing the largest market share. The significant growth of this segment can be attributed to the efficient gene delivery, strong immune response, replication-incompetent viruses, and scalability of adenovirus vaccines compared to other viral vectors. Notably, several collaborations have emerged to enhance immunization efforts, such as the partnership between ReiThera Srl (Italy), the Ragon Institute of Mass General, MIT, and Harvard (U.S.), and the International AIDS Vaccine Initiative (IAVI) (U.S.), which is focused on developing a novel HIV vaccine candidate. 4. Market by Approach: Preventive Vaccines Take the Lead The report distinguishes between preventive vaccines and therapeutic vaccines, with preventive vaccines projected to account for a larger market share by 2024. Preventive vaccines aim to protect individuals from contracting viral or bacterial infections and are vital for maintaining public health. The growth of this segment is fueled by increasing awareness about the importance of immunization, widespread immunization programs, and the rising prevalence of chronic and infectious diseases. Preventive vaccines help induce herd immunity, thereby reducing disease outbreaks and preventing mortality. 5. Market by Indication: Infectious Diseases at the Forefront Page 2 of 5 © Meticulous Research| sales@meticulousresearch.com

  4. Viral Vaccines Market 2024-2031 In terms of indications, the infectious diseases segment is expected to dominate the market by 2024. Infectious diseases remain a significant global health concern, and vaccines play a critical role in reducing morbidity and mortality rates. Vaccination efforts are not only cost-effective but also crucial for global health security. With infectious diseases responsible for over 1.5 million deaths among children under the age of 5 each year, as per the World Health Organization (WHO), the demand for viral vaccines continues to surge. The report underscores the role of pharmaceutical companies in addressing this global challenge. For example, the R21/Matrix-M malaria vaccine, developed by Oxford University (U.K.) and the Serum Institute of India Pvt. Ltd. (India), received a recommendation from WHO's Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG) in October 2023. This is a significant step toward reducing vaccine-preventable diseases globally. 6. Market by Application: Antisense Therapy Gaining Traction The antisense therapy segment is projected to hold the largest market share in 2024. Antisense vaccines are gaining popularity due to their ability to elicit both humoral (antibody-mediated) and cellular immune responses, providing broad- spectrum protection against a variety of pathogens. The growing prevalence of infectious diseases, technological advancements in viral vectors, and increasing healthcare expenditures further fuel the growth of this segment. Discover More About Market Segmentation And Geographic Forecasts By Accessing The Full [PDF] Sample Research Report – https://www.meticulousresearch.com/request-sample- report/cp_id=5920?utm_source=article&utm_medium=social&utm_campaign= product&utm_content=02-10-2024 Competitive Landscape: Key Players Shaping the Future of the Viral Vaccines Market The viral vaccines market is highly competitive, with leading players leveraging innovation and strategic partnerships to stay ahead. Key companies profiled in the report include: •Pfizer, Inc. (U.S.) •AstraZeneca plc (U.K.) •GlaxoSmithKline plc (U.K.) •Sanofi S.A. (Italy) •CSL Ltd. (Australia) Page 3 of 5 © Meticulous Research| sales@meticulousresearch.com

  5. Viral Vaccines Market 2024-2031 •Mitsubishi Tanabe Pharma Corporation (Japan) •Merck & Co., Inc. (U.S.) •Moderna, Inc. (U.S.) •Johnson & Johnson Services, Inc. (U.S.) •Dynavax Technologies Corporation (U.S.) •Serum Institute of India Pvt. Ltd (India) •Emergent BioSolutions, Inc. (U.S.) •Bharat Biotech International Limited (BBIL) (India) •Valneva SE (France) •Regional Insights: North America Dominates the Market Geographically, North America is expected to retain its position as the largest market for viral vaccines by 2024. The region's advanced research infrastructure, presence of leading pharmaceutical companies, and proactive collaborations between research institutes and industry players contribute to its strong market share. Moreover, the establishment of new facilities by key market players and heightened awareness of the importance of vaccination further drive the region's dominance. Conversely, Asia-Pacific is projected to register the highest CAGR during the forecast period. Countries like India and China offer lucrative opportunities for market players due to their burgeoning pharmaceutical and biopharmaceutical industries, the growing number of clinical trials, and rising investments in research and development. The shift towards eClinical solutions in the region, combined with the increasing preference for digital data management, is expected to contribute to substantial market growth. Conclusion: The Road Ahead for Viral Vaccines The viral vaccines market is poised for steady growth, driven by technological advancements, evolving healthcare needs, and increasing government initiatives to bolster immunization programs. With the global healthcare landscape rapidly evolving, industry stakeholders must remain agile and continue investing in research and development to capitalize on emerging opportunities. Read Full Report :- https://www.meticulousresearch.com/product/viral-vaccines- market-5920 About Meticulous Research® Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Page 4 of 5 © Meticulous Research| sales@meticulousresearch.com

  6. Viral Vaccines Market 2024-2031 Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia- Pacific, Latin America, and the Middle East & Africa. The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous- research Page 5 of 5 © Meticulous Research| sales@meticulousresearch.com

More Related